In the BioHarmony Drug Report Database

"Preview" Icon

Esketamine

Spravato (esketamine) is a small molecule pharmaceutical. Esketamine was first approved as Spravato on 2019-03-05. It is used to treat treatment-resistant depressive disorder in the USA. It has been approved in Europe to treat depressive disorder. Spravato’s patents are valid until 2035-09-10 (FDA).

 

Trade Name

 

Spravato
 

Common Name

 

esketamine
 

ChEMBL ID

 

CHEMBL395091
 

Indication

 

depressive disorder, treatment-resistant depressive disorder
 

Drug Class

 

Nmda receptor antagonists; Antidepressants; General anesthetics; Dissociative hallucinogens; Analgesics

Image (chem structure or protein)

Esketamine structure rendering